title: Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study.
abstract: Adjuvant chemoradiotherapy was administered to 26 patients with stage Ic-IV ovarian cancer after radical cytoreductive surgery. All patients received six cycles of carboplatin, epirubicin, and prednimustine and had no evidence of disease after completion of chemotherapy. They received whole-abdominal radiation and radiation to the retroperitoneal lymph nodes. Five (23%) of the patients were discontinued on this protocol because of myelosuppression, progressive disease, or withdrawal. One patient had a small bowel obstruction due to intraperitoneal adhesions. The survival of 10 Stage III ovarian cancer patients who received chemoradiotherapy and were evaluable for assessment of treatment efficacy was retrospectively compared with the survival of 11 Stage III patients who received chemotherapy only. At 36 months, a slight advantage of the chemoradiotherapy versus the chemotherapy-only group was observed (p = 0.11). These preliminary results suggest that adjuvant chemoradiotherapy may prolong the "no evidence of disease" interval of radically operated ovarian cancer patients. Toxicity is acceptable when second-look surgery is avoided and when subsequent radiotherapy is limited to patients with no clinical evidence of disease.
authors.affiliation: Department of Obstetrics and Gynecology, University of Graz, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Pickel
authors.forename: E
authors.initials: E
authors.lastname: Petru
authors.forename: M
authors.initials: M
authors.lastname: Lahousen
authors.forename: H
authors.initials: H
authors.lastname: Stettner
authors.forename: M
authors.initials: M
authors.lastname: Heydarfadai
authors.forename: K
authors.initials: K
authors.lastname: Arian-Schad
authors.forename: A
authors.initials: A
authors.lastname: Hackl
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006402:Hematologic Diseases / Q000209:etiology; D006801:Humans; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000628:therapy*; D010865:Pilot Projects; D011238:Prednimustine / Q000008:administration & dosage; D015996:Survival Rate
chemical_list: D015251:Epirubicin; D011238:Prednimustine; D016190:Carboplatin